
Although most people will be familiar with the role growth hormone (GH) plays in growth during childhood and body composition, few will be aware of the role growth hormone releasing hormone (GHRH) plays in sleep and cognition. Researchers are interested in understanding whether the GHRH system plays a role in deep sleep which could then influence memory and attention in the elderly.
Below we have outlined what has been found from research, what the evidence suggests and what limitations the research has.
GHRH – What is it?
GHRH is a 44 amino-acid peptide secreted by the hypothalamus which acts on the nearby pituitary gland to stimulate GH release. GH will then go on to stimulate release of insulin-like growth factor 1 (IGF-1), primarily from the liver but also the brain.
As the GHRH system has receptors in brain regions associated with sleep regulation and both GH and IGF-1 can enter brain tissue, this has made researchers within the field of sleep medicine and cognitive ageing interested.
GHRH and Deep Sleep
The major release of GH throughout the day occurs shortly after you fall asleep whilst in slow wave (deep) sleep. This has made researchers want to understand whether GHRH can increase deep sleep.
A small study investigated whether GHRH could increase deep sleep in 7 healthy young males. In 1992, males were given GHRH in a sleep lab in Germany. Results showed GHRH increased percentage slow wave sleep during the night compared to placebo (~14% to ~20%). GHRH increased GH release during the night however it reduced cortisol release. Somatostatin (the hormone that opposes GHRH) did not increase GH during the night.
Further research, including animal studies, suggests GHRH is one of the signals that can increase deep sleep. We know that our deep sleep decreases with ageing and so does GH release. It is still being debated whether this is cause and effect or simply part of the overall age related changes.
GHRH and Cognition in the Elderly
The most cited research has come from a group at the University of Washington and VA Puget Sound.
A 2006 study published in Neurobiology of Aging looked at 89 healthy older adults (mean age 68). Results showed that after 6 months of daily GHRH it improved cognition in many domains including working memory and processing speed. This was a placebo controlled study.
A larger trial was carried out in 2012 by Baker et al and published in Archives of Neurology. The study looked at:
137 adults aged between 55-87 years old (76 with normal cognition and 61 with mild cognitive impairment).
Participants received either a synthetic GHRH analogue (tesamorelin) or placebo for 20 weeks. Cognition tests were carried out at baseline, week 10, week 20 and 10 week washout.
The GHRH group had more improvements in composite executive function scores (task switching, working memory and word fluency). Improvements were seen in both the normal cognition and MCI groups compared to placebo. Verbal memory had a positive trend however visual memory was unchanged. IGF-1 levels nearly doubled during treatment however returned to baseline during washout. Body fat decreased and fasting insulin increased in those with MCI.
Evidence
Whilst interesting there are some limitations:
Small effects – At the time of the research commentators were commenting that the effect on cognition was small and may not really make a difference in daily life.
Short term only – The main study was only carried out over 20 weeks. We do not know if longer term benefits would be seen.
Not well replicated – Most of the human cognition research has come from one research group. This would be improved by independent studies replicating the findings.
Mechanism not clear – Although the authors explained that cognition improvements were due to increased IGF-1, this could be an indirect effect. There could be changes in sleep, body composition and metabolism.
Metabolism trade off – Increased fasting insulin reminds us that the GH axis can have multiple systemic effects.
Overall this research shows there is a plausible link between GHRH, sleep and cognition. But we cannot say GHRH analogues can be used as a treatment option for memory or cognitive issues.
Different GHRH Analogues
There are several synthetic versions of GHRH. The analogue used in the 2012 study (tesamorelin) is FDA approved for a specific indication relating to HIV, rather than cognition. Other versions include sermorelin (shorter fragment) and MOD GRF 1-29 (29 amino-acid version with modifications to make it resistant to enzymatic breakdown). MOD GRF 1-29 can only be obtained as a lab research compound.
However, just because one molecule shows an effect doesn’t mean all will. Researchers who buy MOD GRF 1-29 for pre-clinical research should be aware that none of these studies have used this compound in humans. No studies have been carried out in controlled human trials looking at its effects on sleep and cognition. Whilst companies like Generic Peptides provide certificates of analysis for their research compounds they will not tell you how the compound would act in a live system.
What are Researchers Still Trying To Understand?
Can we improve cognition in the elderly by increasing deep sleep? Does the GH axis play a role?
Is the effect on cognition due to increased IGF-1, changes in sleep or both?
Would longer term studies show long term benefits or would the metabolic effects take over?
Do different analogues cause different effects on the brain?
Summary
GHRH stimulates GH release and appears to increase slow wave sleep.
Small studies in humans show GHRH can increase deep sleep in young males.
Controlled studies in the elderly have shown modest improvements in executive function after 20 weeks of GHRH analogue treatment.
Evidence is limited with small effects, short term and not well replicated.
GHRH analogues are not approved for use in cognition. Research compounds are not for human use.
References
Steiger A, et al. Effects of growth hormone-releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in male controls. Neuroendocrinology. 1992;56(4):566–573. PMID 1361964.
Vitiello MV, et al. Growth hormone releasing hormone improves the cognition of healthy older adults. Neurobiol Aging. 2006. PMID 16399214.
Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012 (published online August 6, 2012).
This article is for educational purposes only and is not medical advice.